Long interspersed nuclear element-1 (LINE-1 or L1) is the only active, self-copying genetic element in the human genome—comprising about 17% of the genome. It is commonly called a "jumping gene" or ...

DNA synthesis is vital to several processes in biopharmaceutical innovation, including the development of gene therapies, CRISPR gene editing, antisense oligonucleotides and RNA therapies. The need ...

Boston Consulting Group predicts that the size of the global bioeconomy will be $30 trillion by the end of the decade. One of the instrumental drivers of its rapid growth was the reduction of the cost ...

Despite these advances, the synthesis of DNA nanostructures has remained a largely manual and time-consuming process. Traditional approaches often require the precise mixing of hundreds of unique DNA ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...

Matthew Hayes (Left) is the Chief Technology Officer and founder at Evonetix, a groundbreaking gene synthesis technology company created in 2015, where he deploys his expertise in multi-disciplinary ...

Next-generation gene synthesis could be as transformative for several multibillion-dollar industries as the semiconductor. Over the past 60 years researchers have spent a great deal of time and money ...

- The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences. - Ansa synthesized a 1005 base long oligonucleotide with industry-leading accuracy. - Ansa will be ...

There’s an old saying about a dollar waiting on a dime. In other words, a monumental endeavor may become stuck at some point if a key preliminary element remains unavailable. The saying could be ...